The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Efzimfotase alfa is an investigational enzyme replacement therapy designed to reduce injection volume
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The company plans to submit the vaccine for regulatory review
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The trial will enroll up to 42 patients in Finland across four cohorts
Subscribe To Our Newsletter & Stay Updated
